The DEA’s rejection of rescheduling leaves America at a crossroads. Do we continue allowing an agency with a vested interest in maintaining cannabis prohibition to override scientific evidence on the plant’s medical value? Or do we re-evaluate the necessity of the DEA’s existence altogether?
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10.…
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking…
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves…
But there's more to this image than nostalgia and comedy. What you're looking at in…
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…